government

Evidence page

Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use

U.S. Food and Drug Administration

accessed Sep 18, 2026Updated Sep 19, 2026

Original source

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal

fda.gov

Verification

Verification	Not yet verified
Evidence level	—
Source	government
Link status	Reachable at last check

Official claims are statements by the provider; they are not verified by worldwiki unless marked otherwise. Source policy

Cited by (3)

FactAdipose Tissue: Governing FDA guidance = 'Regulatory Considerations for HCT/Ps: Minimal Manipulation and Homologous Use' (21 CFR 1271.10(a)); July 2020 version, superseding the Nov/Dec 2017 guidance FactSVF-assisted Fat Grafting: Applicable US FDA guidance = Final guidance 'Regulatory Considerations for HCT/Ps: Minimal Manipulation and Homologous Use', July 2020 (supersedes November 2017 version)FactSVF Facial Fat Grafting: Applicable FDA guidance = Regulatory Considerations for HCT/Ps: Minimal Manipulation and Homologous Use (docket FDA-2017-D-6146)